Answers are grounded in this paper and cite their sources.
In recent years, continuous glucose monitoring (CGM) has emerged as a significant topic of discussion within the diabetes community. First introduced in the late 1990s and approved by the Food and Drug Administration (FDA) in 1999, CGM was initially designed for patients with insulin-requiring diabetes. However, as awareness of diabetes grew – partially due to the public journey of pop star Nick Jonas – its potential has also been recognized by a broader audience, including those with noninsulin-requiring diabetes, prediabetes, and even healthy individuals without a formal diagnosis.[1,2] This editorial aims to illuminate the evolution of CGM and its impact on individuals without diabetes. Before delving into the benefits and limitations of CGM, it is crucial to trace its development, particularly in terms of mean absolute relative deviation (MARD), which measures how closely the CGM readings match the actual blood glucose levels, with a lower MARD indicating higher accuracy. Due to those concerns, early CGM devices were approved only for adjunctive use, necessitating frequent calibration with capillary glucose readings. The American Diabetes Association (ADA) reports that the MARD for early CGM devices was approximately 22%. However, with further advancements in accuracy, the Dexcom Seven Plus, approved by the FDA in 2007, had a MARD of 16% and could be worn for 7 days. This was followed by the Dexcom G4, approved in 2012, which improved to a MARD of 13%. Subsequent models, such as the Dexcom G5, G6, and G6 pro, achieved a MARD of 9% with a wear time of 10 days. The latest system, Dexcom 7, demonstrated a MARD of approximately 8.1%, closer to the 5% to 10% range seen with traditional blood glucose meters.[3] Similarly, the FreeStyle Libre Pro, approved by the FDA in 2016, started with a MARD of 12.3%, measuring glucose every 15 min and lasting 14 days. Its newer models have also shown improvements, with FreeStyle Libre 2 achieving a MARD of 9.5% and FreeStyle Libre 3 reaching 7.9%. These refined MARD values, along with the durability and marketing of CGM, have led to more patients with diabetes requiring insulin to use the device to help manage their condition.[4] On the other hand, there are patients with prediabetes, for whom CGM could offer a ray of hope with its substantial potential benefits. It provides a detailed picture of glucose excursions and variability, facilitating the early identification and management of glucose spikes. By helping users identify glucose trends, CGM enables proactive lifestyle changes. Continuous, real-time feedback can motivate individuals to adopt healthier habits, potentially reversing prediabetes. When utilized correctly, CGM serves as an educational tool, increasing awareness of how diet and exercise influence glucose levels, as lifestyle modifications are pivotal in reversing prediabetes. This promising tool can bring optimism to those dealing with prediabetes. However, there currently needs to be a consensus or high-quality evidence supporting the routine use of CGM for managing prediabetes, and the ADA has not included CGM in its guidelines for this condition. The motivational benefits of CGM are most effective for those willing to act on the information it provides.[5] Usability can also be an issue, particularly among specific populations. Some patients, especially older adults, may struggle to navigate mobile applications or electronic devices. In addition, affordability varies tremendously based on insurance coverage.[6] The cost may not be justifiable for some, especially if they can effectively manage lifestyle changes without the device and are content with annual A1C check-ups. Earlier this year, in March 2024, the FDA granted clearance for the first over-the-counter (OTC) CGM launched by Dexcom, Stelo. Shortly after, their competing company Abbott released the second such device, Lingo, available to the public in September 2024.[7] Only 6 months apart, not only has CGM become an OTC product, but there are two brands that one can choose from. This raises questions about how increased accessibility will impact the general population, as anyone can now acquire the device, including healthy individuals who may never have received a diabetes diagnosis. A prospect side is that healthy individuals can reap its potential benefits, which are not limited to optimizing overall health, monitoring the effects of food on glucose levels, and preventing future glucose-related issues. The system provides personalized insights to help individuals tailor their dietary and lifestyle choices based on their unique responses. This increased awareness can encourage healthier decisions, such as choosing nuts or fresh carrots instead of sugary or fatty snacks. It may also motivate individuals to engage in physical activities rather than remain sedentary. With a user-friendly interface compatible with smartphones, users can easily access data at their fingertips, showing immediate results. CGM can provide a proactive approach to health management for healthy individuals, offering insights into how their lifestyle choices affect their glucose levels and empowering them to make healthier habits a part of their daily routine. In the US, Dexcom’s Stelo, with a MARD of 8.3%, is available for a monthly subscription of $89 or a one-time order of two sensors for $99, each of which can be worn for up to 15 days. Abbott’s Lingo, a competing device with a MARD of 9.2%, is priced at $49 for 2 weeks, $89 for 4 weeks, and $249 for 12 weeks; each biosensor can be worn for up to 2 weeks.[7,8] After purchasing a CGM, it is crucial to receive adequate education to ensure that it provides more than just a collection of numbers. Healthy individuals who typically do not visit doctors frequently may need self-education in interpreting their data, which could lead to inaccurate assessments. This misinterpretation could result in anxiety regarding glucose levels and health, causing users to become overly fixated on these numbers without understanding their actual meaning. Therefore, comprehensive and accessible training on data interpretation is critical to ensure that CGM serves as an advantage rather than a downside. With the shortage of endocrinology specialists, educating patients about CGM falls on primary care physicians, who already have much on their plate. This situation could potentially increase the burden on the healthcare system.[7] This leads to an important question: Why should one invest time, money, and energy into monitoring rapidly changing numbers when most individuals without diabetes do not require constant glucose monitoring? Similar to individuals with prediabetes, there are currently no established guidelines for using CGMs as preventive medicine for the healthy population. Positive lifestyle choices, such as regular exercise and a balanced diet, are always encouraged for good health.[9] While CGMs can be powerful tools for managing glucose levels among various populations, their clinical benefits must be balanced against financial costs, potential anxiety, and each patient’s unique needs. Tailoring CGMs to individual circumstances and patient goals is not just important; it is essential for maximizing benefits and minimizing drawbacks. Continued studies are necessary to fully realize this innovative technology’s potential advantages. It is salient to remember that each patient is unique, and their needs and situations should be considered when deciding whether to use a CGM.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: